Definium Therapeutics (DFTX) Q1 2026 Earnings Report

The call emphasizes strong clinical momentum (multiple Phase III programs with imminent topline readouts, Breakthrough Therapy designation in GAD, high statistical power in key studies), a clear commercialization plan and a solid cash position ($373.4M runway into 2028). These positives are tempered by materially higher operating expenses and a sizable YOY increase in net loss (driven by program investment and a non-cash warrant valuation change), design-related placebo risk from Phase II, and remaining regulatory and payer uncertainties that could affect timing and labeling. On balance, management’s message is forward-looking and execution-focused with meaningful near-term inflection points.

The company reiterated near-term clinical and financial guidance: three pivotal DT120 toplines are expected imminently—EMERGE (MDD, enrollment 149) later this quarter with a 6‑week primary endpoint, VOYAGE (GAD, enrollment 214) expected early Q3 and PANORAMA (GAD, >200 enrolled) expected late Q3 with 12‑week primaries—and a planned HAVEN PTSD study in 2027; VOYAGE and PANORAMA are now powered at ≥99% to detect a 5‑point placebo‑adjusted difference (EMERGE was powered at 80% with significance possible at ~3 points), the Phase III program targets durability of a single administration for at least 12 weeks (Part B follows patients up to one year and allows up to four additional open‑label treatments), Phase II showed 12‑week durability at 100 µg, and DT120 holds Breakthrough Therapy designation in GAD; financially Q1 2026 R&D was $41.5M (up $18.1M YoY, $15.2M of which was DT120), G&A $17.7M (up $8.9M YoY), net loss $77.1M (vs $23.3M), a $20.0M mark‑to‑market warrant impact tied to a share price rise from $13.39 to $18.90, cash and investments of $373.4M supporting runway into 2028, market sizing noted ~4.2M U.S. adults with ≥2 prior treatment failures and a 1% TAM capture modeled as ≈$2B annual revenue, operationally aiming for a 5–8 hour patient journey (vs 10–12 in Phase II) with a single in‑person monitor supported by remote backup, and a potential DEA scheduling acceleration that could shave roughly 90 days from post‑approval access.